|Tissue Science Laboratories
||EPS - Basic
||Market Cap (m)
Tissue Science Laboratories Share Discussion Threads
Showing 51 to 73 of 75 messages
bought this as a Xmas tip from Charles Stanley at the start of 07, watched it trickle down since. Most chuffed to exit on a nice profit.
|A sensible decision from the management and a good price negotiated. The alternative was not too cheerful as the company would have run out of cash in the next few months and considerable dilution would have followed.
I had written this one off a long time ago, so a nice save from my perspective.|
|But quarter 1 sales are up 88%. Seems a good gamble for quick gain to +/- 140 p. ?|
|Although TSL is atracting some interest at these lower price levels(Investors Chronicle 12 April 2007"BUY",there does seem some doubt over its flagship product-Permacol.A watching brief remains,maybe,the prudent option.http://taylorandfrancis.metapress.com/content/q614813373137x25/|
|charles stanley doesn't seem to know how much this stock is worth http://www.market-insider.net/?p=1791|
|Charles Stanley has worked through the numbers a can see some real value in this one. Because the firm is not yet profitable, it bases its valaution on a multiple of sales.
Broker says: 'On that basis and on the assumption that our projection of sales is correct, we could calculate a share price of
between 117p and 140p. 'That implies very large potential upside in the shares.'
Stock is currently trading at around 75p.|
|broker buy,mail on Sunday|
|Other comment: General Motors aims to do more with less - How China is ushering its biggest bank to market - Fidelity's fiercely independent offspring has global ambitions - Suggestions that Group 4 Securicor could bid for Prosegur of Spain - Vague bid rumours lift Big Yellow - Talk that Tissue Science Laboratories could become a bid target
The above taken from a summary of stories in today's Financial Times!!
Managed to dig out a couple buys yesterday but online limit dropped to 750 at the moment.
|£500,000 vote of confidence from the Chairman and the market seems to like it.|
|Are they being serious or what!!!! "This placing has been undertaken in response to investor feedback that they
would like to provide the business with additional working capital headroom.
Whilst we had no specific need for additional financing, it does strengthen our
financial position and will benefit the business going forward. We are very
pleased at the high level of interest we had from investors to the Placing,
which was heavily oversubscribed, and believe we have struck the right balance
in terms of the amount raised and setting the placing price at the current bid
|Slap it's based on many years of seeing money transfered from the weak to the strong! so beware, this cpmpany could hurt your pocket unless you are very nimble!|
|jotoha1, let's hope the sales force succeed. Where did you get that Fair value from? or is it your cynical humour?
|ouch, glad I,m not holding.|
|Some very good news flow over the past two weeks. The first piece of news last week was largly overlooked. Some recent buying following todays news has moved the share price and there should be more to come on the back of this.|
|results tomorrow. wonder if they are going to be as good as lifc? if so, this is headed 30% higher at least|
|Hey, pork belly. Sounds like you have a vested interest. Any ideas why they have risen 18% today? Or is it no skin off your nose? :-)|
Thur, 08 Sep 05
Tissue Science Laboratories (TSL:AIM)
160p | Market value £46.3 million
TSL specialises in human tissue replacement and repair from pig-skin, or porcine dermis to give its technical name.
It may not sound very kosher but it is a huge market already and will only get bigger as the technology is transferred to plastic and cosmetic surgery (nose jobs, for example).
TSL already has a marketing agreement with American company Porex Surgical for its Enduragen implant, launched at the American Society of Plastic Surgeons Meeting in April, and others should follow. It also has aspirations for wrinkle treatment, with alternatives to Allergen's popular Botox treatment.
In the meantime, TSL should burst into profit next year thanks to its existing
products in its neurology, gynaecology and general surgery markets, which alone could catapult the shares to a significantly higher level.|
|LIFC results this morning absolutely astounding. suggests that TSL is probably doing very well also, but not reflected in the share price. looks like a good opportunity here|
|check out LIFC on nasdaq. exploding higher on great sales. same sector as TSL|
|Strange that the price should drop on news of the directors' options. There seems to be no logic here. An opportunity?|
|Anyone still watching this?|
|V good results. Close now to break even. Confident outlook.
Assuming growth slows from 78% to 50% and margins remain the same % and costs rise by £1m we could make around £1m PBT (should be no tax anyway with losses carried forward). If growth rates are maintained could see PBT of around £2m.|